FACULTAD DE CIENCIAS BIOMÉDICAS Y DE LA SALUD
Facultad
Emory University
Atlanta, Estados UnidosPublicaciones en colaboración con investigadores/as de Emory University (17)
2024
-
Correction to: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer (npj Breast Cancer, (2022), 8, 1, (98), 10.1038/s41523-022-00467-1)
npj Breast Cancer
-
Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies
Blood
-
Factors Associated With Coronary Angiography Performed Within 6 Months of Randomization to the Conservative Strategy in the ISCHEMIA Trial
Circulation: Cardiovascular Interventions, Vol. 17, Núm. 6, pp. 457-473
-
Final Results from the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression
Journal of Clinical Oncology, Vol. 42, Núm. 15, pp. 1738-1744
-
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Annals of Oncology, Vol. 35, Núm. 1, pp. 66-76
2023
-
Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer
European Journal of Cancer, Vol. 178, pp. 23-33
2022
-
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
Breast Cancer Research and Treatment, Vol. 195, Núm. 2, pp. 127-139
-
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis
npj Breast Cancer, Vol. 8, Núm. 1
-
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
npj Breast Cancer, Vol. 8, Núm. 1
2021
-
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
Annals of Oncology, Vol. 32, Núm. 9, pp. 1148-1156
-
Heterozygous ANKRD17 loss-of-function variants cause a syndrome with intellectual disability, speech delay, and dysmorphism
American Journal of Human Genetics, Vol. 108, Núm. 6, pp. 1138-1150
-
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
npj Breast Cancer, Vol. 7, Núm. 1
2020
-
Epilepsy and Electroencephalographic Abnormalities in SATB2-Associated Syndrome
Pediatric Neurology, Vol. 112, pp. 94-100
2015
-
Candida infective endocarditis: An observational cohort study with a focus on therapy
Antimicrobial Agents and Chemotherapy, Vol. 59, Núm. 4, pp. 2365-2373
2013
-
Treatment of idiopathic pulmonary fibrosis with Ambrisentan: A parallel, randomized trial
Annals of Internal Medicine, Vol. 158, Núm. 9, pp. 641-649
2009
-
Circadian clock genes of goldfish, carassius auratus: CDNA cloning and rhythmic expression of period and cryptochrome transcripts in retina, liver, and gut
Journal of Biological Rhythms, Vol. 24, Núm. 2, pp. 104-113
2006
-
Introduction
Journal of Acquired Immune Deficiency Syndromes